StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)

Thu, 18 Jun 2026 06:47:38 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $55.00 price target on Cogent (NASDAQ: COGT).

The analyst commented: "At EHA, Cogent presented the primary results from the Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). Per the oral presentation, bezuclastinib (n=81; 35% prior TKI) generated a high response rate (54% ORR [24% CR + CRh] per mIWG-MRT-ECNM criteria), with consistent efficacy across AdvSM subtyped (see Figure 1 below), and demonstrated marked reductions in objective measures of disease (i.e., 89%, 89%, and 91% of patients achieving a ≥50% reduction in serum tryptase, bone marrow mast

Stifel Reiterates Buy Rating on Cogent (COGT)

Mon, 15 Jun 2026 09:25:56 -0400

(Updated - June 15, 2026 9:25 AM EDT)

Stifel analyst Laura Prendergast reiterated a Buy rating and $45.00 price target on Cogent (NASDAQ: COGT).

The analyst commented, "Today, COGT announced detailed and updated clinical results including detailed pathobiology from the registration-directed APEX clinical trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) - see poster and slides here. These data will be presented at the 2026 European Hematology Association (EHA) in Stockholm, Sweden (June 11-14, 2026). NDA submission of bezuclastinib for the AdvSM population is planned imminently (in June 2026).See full report for comp tables comparing APEX results to AYVAKIT (Blueprint

Cogent Biosciences presents preclinical data on JAK2 inhibitor at EHA

Fri, 12 Jun 2026 08:01:41 -0400

Cogent Biosciences Inc. (NASDAQ: COGT) presented preclinical data for its JAK2 V617F inhibitor CGT1145 at the European Hematology Association Congress in Stockholm on June 12.

The poster presentation highlighted CGT1145's selectivity profile, showing greater than 100-fold selectivity over JAK2 wild-type and JAK1/3 isoforms. The compound demonstrated high oral bioavailability and low clearance across species in preclinical studies.

JAK2 V617F represents a genetic mutation found in approximately 95% of patients with polycythemia vera and 50% of patients with primary myelofibrosis or essential thrombocythemia. These conditions fall under BCR-ABL-negative myeloproliferative neoplasms.

"This highly selective, potent inhibitor of JAK2 V617F has the potential to address the

Cogent Biosciences presents preclinical data on JAK2 inhibitor at EHA

Fri, 12 Jun 2026 08:01:41 -0400

Cogent Biosciences Inc. (NASDAQ: COGT) presented preclinical data for its JAK2 V617F inhibitor CGT1145 at the European Hematology Association Congress in Stockholm on June 12.

"This highly selective, potent inhibitor of JAK2 V617F has the potential to address the

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Fri, 12 Jun 2026 08:01:00 -0400

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -

- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -

WALTHAM, Mass. and BOULDER, Colo., June 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential best-in-class JAK2 V617F mutant-selective inhibitor in a poster presentation at the 2026 European Hematology Association (EHA) Congress taking place in Stockholm, Sweden,

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Fri, 12 Jun 2026 08:01:00 -0400

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -

- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Fri, 12 Jun 2026 08:01:00 -0400

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -

- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Fri, 12 Jun 2026 08:01:00 -0400

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors -

- Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 -

Cogent Biosciences reports 65% response rate in mastocytosis trial

Fri, 12 Jun 2026 08:00:42 -0400

Cogent Biosciences Inc. (NASDAQ: COGT) reported updated results from its APEX pivotal trial of bezuclastinib in patients with advanced systemic mastocytosis. The trial showed a 65% objective response rate using modified International Working Group criteria and an 81% response rate using pure pathological response criteria.

As of March 31, 2026, 81 patients with advanced systemic mastocytosis received 150 mg of bezuclastinib in the trial's second part. The group included 57 patients with systemic mastocytosis with associated hematologic neoplasm, 11 patients with aggressive systemic mastocytosis and 13 patients with mast cell leukemia.

The treatment demonstrated reductions in disease markers, with 89% of patients

Cogent Biosciences reports 65% response rate in mastocytosis trial

Fri, 12 Jun 2026 08:00:42 -0400

The treatment demonstrated reductions in disease markers, with 89% of patients

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Fri, 12 Jun 2026 08:00:00 -0400

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria –

-- Bezuclastinib demonstrated a powerful effect on mast cell burden with 91% of patients achieving ≥50% reduction in variant allele frequency and 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates –

-- Bezuclastinib continues to demonstrate a favorable safety and tolerability profile –